Introduction
============

Cervical cancer (CC) is one of the most prevalent and malignant types of cancer in women, and is the second most common malignancy in women with \>50 million new cases each year ([@b1-ol-0-0-10527]). Although cervical screening programs in certain developed countries have contributed to the detection and prompt treatment of cervical abnormalities, the morbidity and mortality of CC has continued to increase on a yearly basis, particularly in developing countries ([@b2-ol-0-0-10527]).

Tumor biomarkers have been used for the clinical diagnosis of cancer during the early stages, and have been demonstrated to greatly improve the effectiveness of treatments and thus the quality of life. Of these biomarkers, squamous cell carcinoma antigen (SCCA) is a predictive and prognostic factor for CC ([@b3-ol-0-0-10527]). However, SCCA exhibits low sensitivity, resulting in a relatively high risk of missed diagnosis of CC during screening ([@b4-ol-0-0-10527],[@b5-ol-0-0-10527]). A previous study indicated that the levels of SCCA were also increased in other types of cancer, including breast cancer ([@b5-ol-0-0-10527]). Sugar chain antigen 125 (CA-125) was used for the diagnosis of ovarian carcinoma and its sensitivity was primarily based on the staging of ovarian malignancies ([@b6-ol-0-0-10527]). However, it has been reported that the expression levels of CA-125 were also elevated in other malignancies, including \~10.4% of benign ovarian tumors ([@b7-ol-0-0-10527]). Therefore, it is necessary to screen for more specific indicators that could predict the prognosis and assist in the diagnosis of CC.

Researchers have attempted to identify more accurate and simple serum indices, such as serum vascular endothelial growth factor levels ([@b8-ol-0-0-10527]) and pre-treatment serum hemoglobin levels ([@b9-ol-0-0-10527]), to assist in the diagnosis and prognosis of CC. However, there remains a lack of specific predictors for the pathogenesis of CC and thus more useful markers are required for improved early diagnosis. Therefore, based on the results of the aforementioned previous studies ([@b8-ol-0-0-10527],[@b9-ol-0-0-10527]), the present study further investigated the predictive factors associated with CC progression.

The aim of the present study was to identify biomarkers to predict and detect progression of CC through re-analysis of clinical serum indices using a multistage approach. A total of four serological tumor markers, including sugar chain antigen 199 (CA-199), CA-125, α-fetoprotein (AFP) and carcino-embryonic antigen (CEA) were selected in the present study to assess their diagnostic specificity for CC. Furthermore, the present study also analyzed three potential metabolic factors, including alkaline phosphatase (ALP), cholesterol and triglyceride (TG) for the prediction of CC progression. The present study systemically analyzed the association between seven types of serum indices and CC, in order to assess whether they could be used as early prediction factors of CC.

Patients and methods
====================

### Study population

The present study included 259 patients with CC and 390 healthy women recruited from June 2012 to June 2017 at The Affiliated Hospital of Jiangsu University (Zhenjiang, China). The characteristics of patients with CC and healthy control women are summarized in [Table I](#tI-ol-0-0-10527){ref-type="table"}. The pathological classification of CC was based on the morphology of cervical tissues and cells, and confirmed by two independent pathologists at The Affiliated Hospital of Jiangsu University. Patients with CC were divided into three groups: i) Stage I; ii) Stage II; and iii) Stage III/IV, according to the International Federation of Gynecology and Obstetrics (FIGO) staging system ([@b10-ol-0-0-10527]). Additionally, patients with CC and healthy controls were divided into three age groups: \<40 years old, 40--50 years old and \>50 years old. The present study was approved by The Ethics Committee for Biomedical Research at Affiliated Hospital of Jiangsu University (approval no. 20120019), and conducted according to the guidelines for clinical retrospective studies ([@b11-ol-0-0-10527]). All participants were fully informed of the purpose and significance of the study. Written informed consent was obtained from all the participants for participation.

### Data collection

The accrual data collection was retrospective. Inclusion criteria for patients with CC were: i) Patients diagnosed with CC; ii) FIGO Stage I--IV; iii) data collection prior to radical surgery for CC from patients not treated with radiotherapy or chemotherapy; and iv) no abnormal fever or infection present. Exclusion criteria for patients with CC were: i) Data collection following radical surgery for CC or postoperative recurrent cases of CC; ii) patients who have undergone radiotherapy or chemotherapy; iii) patients with other malignant tumors, including ovary masses and uterine fibroids; iv) patients with other diseases, including hepatitis, chronical disorder, inflammatory infection, endometriosis, uterine fibroid and cervical intraepithelial neoplasia, which would have affected serum indices used in the present study and v) patients exceeding the normal upper limit of aspartate aminotransferase (AST) and alanine transferase (ALT). The average age of patients with CC tested for serum indices was 50.6±11.3 years. Data for healthy women were collected from the physical examination center, with an average age of 35.8±9.7 years. No organic lesions or abnormal alterations were identified during the physical examination of the healthy women.

### Hematoxylin and eosin (H&E) staining

Briefly, cervical tissues were fixed in 4% paraformaldehyde at room temperature for 40 min, embedded in paraffin and cut into 5-µm-thick sections. After deparaffinization and rehydration, sections were stained with hematoxylin solution for 5 min followed by 5 dips in 1% acid ethanol (1% HCl in 70% ethanol) and then rinsed in distilled water at room temperature. Then the sections were stained with eosin solution for 3 min and followed by dehydration with graded alcohol and clearing in xylene at room temperature. The samples were mounted with neutral balsam and visualized using a bright-field fluorescent microscope (×100 magnification; Axioskop 2 Plus; Carl Zeiss AG, Oberkochen, Germany).

### Detection of serum indices

For detection of serum indices, 24 h prior to commencement of the program, and 48 h after the last exercise training session and after 12 h of fasting, 5-ml blood samples were collected from the brachial veins of the participants between 8 and 10 a.m. Samples were poured into testing tubes without an anticoagulant, to allow the serum to separate. To minimize the time the samples were kept in laboratory conditions, after a 5-min incubation at room temperature, the sample was immediately centrifuged with 1,500 × g at 4°C for 5 min and the serum solution was divided after blood clotting. Subsequently, the resulting serum was used to determine the levels of CA-199, CA-125, AFP, CEA, ALP, cholesterol, TG, ALT, AST and estradiol. Serum indices were measured at the same time-point using an immunochemiluminescence detection system (i2000-SR; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA) and an automated biochemical analyzer (AU5800; Beckman Coulter, Inc., Brea, CA, USA).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from cervical tissues using RNAiso Plus (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer\'s protocol. Total RNA was reverse transcribed into cDNA at 37°C for 15 min followed by 85°C for 5 sec using a Superscript RT kit (Takara Biotechnology Co., Ltd.) and amplified using the SYBR Premix Ex Tag^™^ kit (cat. no. RR420B; Takara Biotechnology Co., Ltd.), under the following conditions: Pre-denaturation at 95°C for 30 sec; 40 cycles of denaturation at 95°C for 3 sec, annealing at 60°C for 30 sec and extension at 72°C for 60 sec. The following primers were used for the amplification of tissue non-specific isozyme ALP (TNALP): Forward, 5′-ACTCTCCGAGATGGTGGTGGTG-3′ and reverse, 5′-CGTGGTCAATTCTGCCTCCTTCC-3′. GAPDH was used as an internal control with the following primers: Forward, 5′-ACCCAGAAGACTGTGGATGG-3′ and reverse, 5′-TTCAGCTCAGGGATGACCTT-3′. The relative changes in gene expression were calculated using the 2^−ΔΔCq^ method ([@b12-ol-0-0-10527]).

### Statistical analysis

Data are presented as the mean ± standard deviation. Odds ratios (ORs) and 95% confidence intervals (CIs) were analyzed using logistic regression. Differences between two groups were calculated using a Student\'s t-test. Differences for the comparison of multiple groups were calculated using one-way ANOVA with a post-hoc Bonferroni test. Data were analyzed using SPSS software (version 22; IBM Corp., Armonk, NY, USA). Experiments were repeated at least three times. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Structure of cervical tissue in normal controls and patients with CC

To investigate the structure of cervical tissue in the normal controls and patients with CC, cervical tissue was stained using H&E. Histological analysis of the ectoendocervical squamocolumnar (SC) junction from normal adults revealed a discrete population of cuboidal epithelial cells at the interface of the ectocervix and endocervix ([Fig. 1A](#f1-ol-0-0-10527){ref-type="fig"}). Previously, gene expression profiling separated the SC junction cells from the squamous and columnar cells, indicating significant differences between the two types of cells ([@b13-ol-0-0-10527]). In patients with cervical squamous cell carcinoma (SCC) and cervical adenocarcinoma (AC), the SC junction disappeared and was replaced with tumor cells ([Fig. 1B and C](#f1-ol-0-0-10527){ref-type="fig"}).

### Re-analysis of potential serum indices for CC

To identify novel clinical predictive factors for patients with CC, the present study systemically used a multistage re-analysis strategy of seven serum indices ([Fig. 2](#f2-ol-0-0-10527){ref-type="fig"}). A total of four serological tumor markers, including CA-199, CA-125, AFP and CEA were used in the present study to assess their specificity for CC. Furthermore, three potential metabolic factors, including ALP, cholesterol and TG were also analyzed for the prediction of CC progression.

The expression levels of CA-125 (P=0.035), CA-199 (P=0.011), AFP (P=0.043), ALP (P\<0.001), cholesterol (P=0.017) and TG (P\<0.001) were significantly different between healthy women and patients with SCC. Furthermore, for healthy women and patients with AC, ALP (P=0.001), cholesterol (P=0.002) and TG (P=0.015) expression levels changed significantly ([Table II](#tII-ol-0-0-10527){ref-type="table"}).

### Age variation and CC

Age is a significant risk factor for tumorigenesis ([@b14-ol-0-0-10527]). The results of the present study indicated that body homeostasis was altered with age. In normal control women, CA-125, CA-199, ALP, cholesterol and TG indices were significantly different (P\<0.05) between the \<40 years old age group and the \>50 years old age group ([Table III](#tIII-ol-0-0-10527){ref-type="table"}).

To study the early diagnostic factors that are independent of age, the present study aimed to identify serum indices using two criteria: There was no statistical difference in normal control patients (P\>0.05); and there was a statistical difference in patients with CC (P\<0.05; [Table IV](#tIV-ol-0-0-10527){ref-type="table"}; [Fig. 2](#f2-ol-0-0-10527){ref-type="fig"}). Comparing the \<40 years old age group with the 40--50 years old age group ALP did not change significantly in normal women, but increased significantly in patients with SCC. Taken together, the present data demonstrated that ALP may be a potential predictive factor for the occurrence and progression of CC, particularly in women with SCC among the 40--50 years old age group.

### FIGO staging and CC

To investigate the association between FIGO staging and CC, the present study further analyzed serological CA-125, CA-199, AFP, ALP, cholesterol and TG levels in patients with SCC, and measured ALP, cholesterol and TG in patients with AC.

For patients with SCC ([Table V](#tV-ol-0-0-10527){ref-type="table"}), only ALP and TG levels increased significantly from Stage I to Stage III/IV CC compared with the normal controls. Furthermore, only ALP and cholesterol levels significantly increased in patients with FIGO Stage I AC compared with the normal controls ([Table VI](#tVI-ol-0-0-10527){ref-type="table"}).

### Expression pattern of ALP in CC

Using the re-analysis strategy, the present study demonstrated that ALP was a potential factor, which may predict the tumorigenesis of CC. Despite the ALP expression levels not exceeding the upper limits of the normal recommended level, the present results indicated that the ALP expression level increased in patients with SCC (P\<0.001) and AC (P\<0.05) compared with the normal controls ([Fig. 3A](#f3-ol-0-0-10527){ref-type="fig"}). As shown in [Fig. 3B](#f3-ol-0-0-10527){ref-type="fig"}, the ALP expression level was significantly increased between the normal controls and patients with SCC in the 40--50 years old group (P\<0.001) and the \>50 years old group (P\<0.01). Although the expression levels of ALP also increased with age between the normal controls and patients with AC, the difference was not statistically significant.

As demonstrated by the FIGO staging analysis, the expression levels of ALP were significantly increased in patients with SCC of different FIGO stages, when compared with the normal controls (all P\<0.001; [Fig. 3C](#f3-ol-0-0-10527){ref-type="fig"}). At present, the number of AC cases for comparison across the FIGO stages was limited, and a larger sample size is required to further confirm the significance of ALP and other serum indices. The present study also detected the relative mRNA expression level of the major type of ALP isozyme, TNALP, between the normal control and CC tissues. The RT-qPCR results indicated that TNALP mRNA expression levels were significantly increased in CC tissues compared with normal cervical tissues ([Fig. 3D](#f3-ol-0-0-10527){ref-type="fig"}; P\<0.01). In summary, the results demonstrated that ALP might be a reliable early predictive factor for detecting the development of CC, particularly in 40--50 year-old women.

### Adjusted assessment of the serum indices for CC

Liver function is an important factor associated with progression of numerous diseases and tumorigenesis ([@b15-ol-0-0-10527]). A recent study demonstrated that serological ALP and AST expression levels were significantly increased in patients with gastric cancer ([@b16-ol-0-0-10527]). Similarly, the present study confirmed that ALP expression levels were also increased in patients with CC. To exclude the effects of liver dysfunction on ALP expression, the present study also assessed seven serum indices between normal control women and patients with CC using adjusted AST and ALT factors (excluding cases exceeding the normal upper limit of AST and ALT). The present data indicated that the seven serum indices between the normal control women and patients with CC exhibited similar results in the adjusted assessment ([Table VII](#tVII-ol-0-0-10527){ref-type="table"}).

Discussion
==========

In the present study, to determine novel clinical predictive factors for the development of CC, a multistage re-analysis strategy of seven serum indices was systematically conducted. The expression levels of CA-125, CA-199, ALP, cholesterol and TG significantly increased in patients with SCC. In addition, the expression levels of AFP were significantly decreased in patients with SCC. In patients with AC, ALP, cholesterol and TG expression levels significantly increased compared with the normal controls. According to age variation (normal, P\>0.05; CC, P\<0.05) and FIGO staging (P\<0.05), the combined analysis results demonstrated that ALP appears to serve a role in CC. ALP expression significantly increased in patients with SCC and AC compared with the normal controls, indicating its potential role in the diagnosis of CC.

ALP is a member of the superfamily of metalloenzymes, which catalyze the hydrolysis of phosphoric acid. In humans, there are four types of ALP isozyme, including TNALP, which is primarily expressed in bone tissue, the liver and kidneys, intestinal-type ALP, placental-type ALP and germ cell ALP ([@b17-ol-0-0-10527]). TNALPs in the bone tissue and liver account for \>90% of serum ALP and are the most abundantly expressed isoforms in the serum ([@b18-ol-0-0-10527]). Previous studies have indicated that ALP is a prognostic factor in predicting overall survival in advanced prostate cancer ([@b19-ol-0-0-10527],[@b20-ol-0-0-10527]). However, the role and mechanism of ALP in tumor pathogenesis remain unclear. A previous study demonstrated that ALP functioned as an ectoenzyme in human osteosarcoma cells ([@b21-ol-0-0-10527]). Another previous study showed that the tumor-derived alkaline phosphatase, biomineralization associated (ALPL) gene, encoding the TNALP protein, was associated with disease-free survival in metastatic prostate cancer and that ALPL promoted the pathogenesis of prostate cancer ([@b22-ol-0-0-10527]). Osteoblasts abundantly express ALP, which can hydrolyze inorganic pyrophosphate and thus, affect bone mineralization, indicating its roles in osteoblastic activity ([@b23-ol-0-0-10527]).

Recently, evidence indicated that TNALP could regulate cranial base growth and synchondrosis maturation via mitogen-activated protein kinase (MAPK) signalling ([@b24-ol-0-0-10527]). Previous studies have also indicated the role of MAPK signaling in tumorigenesis ([@b25-ol-0-0-10527]--[@b28-ol-0-0-10527]), and demonstrated that oncogenes promote tumor growth and metastasis through the MAPK signaling pathway ([@b29-ol-0-0-10527]). Ectopic activation of the MAPK signaling pathway enhances the progression of cancer ([@b30-ol-0-0-10527]). Furthermore, epidermal growth factor receptor regulated matrix metalloproteinase 1 expression via the MAPK/extracellular signal-regulated kinase signaling pathway in SiHa cells, which has been shown to serve a role in tumor invasion, metastasis and angiogenesis ([@b31-ol-0-0-10527]).

CC is a disease caused by multiple pathogenic factors, including age, human papillomavirus (HPV) infection, FIGO stage and menopausal status ([@b32-ol-0-0-10527]). The present study provided a multiple-stage screening strategy for exploring predictive factors by systematic re-analysis of serum indices, and two key pathogenic factors were selected for the second round of screening. ALP was identified as a potential predictor for CC progression. Combined analysis of ALP with other factors, including HPV infection and cytological examination may optimize the diagnosis of CC. Furthermore, serum ALP levels are determined as part of a routine examination in hospitals and the present study suggested that even routine tests can reveal the occurrence of CC, providing important information for early diagnosis of CC. However, more accurate data acquisition is required to confirm the results of the present study and further elucidate the mechanism underlying the development of CC. Additionally, estradiol was determined to be an important factor for affecting ALP levels between normal women and CC in pre-menopausal women (data not shown), and thus, the correlation between estradiol and ALP levels in normal controls and patients with CC requires further analysis in future studies.

The present study identified elevated expression levels of ALP in patients with SCC and AC compared with the normal controls. High levels of serum ALP may influence tumorigenesis and may be an important predictive factor in CC. Further studies may focus on the role and mechanism of increased expression of TNALP in CC. The present study provided novel insight into determining an association between ALP and CC.
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![Representative histological haematoxylin and eosin staining of the adult cervix. (A) Normal cervical tissue with squamous, ectoendocervical squamocolumnar junction and columnar cells (red arrows). (B) SCC cervical tissue with representative nidus (blue arrows). (C) AC cervical tissue with representative nidus (black arrows). The magnified views (×200) are representative structures, which are indicated by the arrows. SCC, squamous cell carcinoma; AC, cervical adenocarcinoma.](ol-18-03-2356-g00){#f1-ol-0-0-10527}

![A flow chart of the re-analysis strategy. The re-analysis strategy assessed seven different serum indices. Further verification was based on age variation and The International Federation of Gynecology and Obstetrics staging. CC, cervical cancer; SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; ASC, adenosquamous cervical carcinoma; CA, sugar chain antigen; AFP, α fetoprotein; CEA, carcino-embryonic antigen; ALP, alkaline phosphatase; TG, triglyceride.](ol-18-03-2356-g01){#f2-ol-0-0-10527}

![ALP expression level is significantly increased in patients with CC. (A) ALP expression level in normal controls, and patients with SCC and AC by biochemical index detection. (B) Analysis of ALP expression level by age bracket. (C) Analysis of ALP expression level by The International Federation of Gynecology and Obstetrics staging in SCC. (D) Relative mRNA expression level of TNALP in normal cervical tissues and CC tissues. Data are presented as the median and the interquartile range. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. n.s., not significant; ALP, alkaline phosphatase; CC, cervical cancer; SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; TNALP, tissue non-specific isozyme ALP.](ol-18-03-2356-g02){#f3-ol-0-0-10527}

###### 

Characteristics of normal controls and patients with CC.

                                              CC                        
  -------------------------------- ---------- ------------- ----------- ----------
  Participants, n (%)              390        235 (90.7%)   23 (8.9%)   1 (0.4%)
  Age, mean ± standard deviation   35.8±9.7   50.7±11.3     50.8±11.0   38
  Age, n                                                                
  \<40                             258        32            5           1
  40--50                           94         102           7           N/A
  \>50                             38         101           11          N/A
  FIGO stage, n (%)                N/A        235 (90.7%)   23 (8.9%)   1 (0.4%)
  I                                N/A        119 (45.9%)   16 (6.2%)   N/A
  II                               N/A        90 (34.7%)    6 (2.3%)    N/A
  III/IV                           N/A        26 (10.1%)    1 (0.4%)    1 (0.4%)

CC, cervical cancer; SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; ASC, adenosquamous cervical carcinoma; FIGO, The International Federation of Gynecology and Obstetrics.

###### 

Comparison of the seven serum indices in normal controls and patients with cervical cancer.

                Normal   SCC             Normal vs. SCC   AC              Normal vs. AC                                                                                                                 
  ------------- -------- --------------- ---------------- --------------- ---------------------- ---------------------------------------------------------- ---- --------------- ---------------------- -----------------------------------------------------
  CA-125        246      16.530±8.573    137              29.923±73.543   1.028 (1.011--1.044)   0.035                                                      16   24.644±29.386   1.037 (1.007--1.068)   0.288
  CA-199        220      10.614±7.762    114              16.603±24.190   1.026 (1.008--1.044)   0.011^[a](#tfn2-ol-0-0-10527){ref-type="table-fn"}^        12   10.497±6.714    0.998 (0.925--1.077)   0.959
  AFP           387      3.487±2.475     129              3.008±1.764     0.897 (0.806--0.998)   0.043^[a](#tfn2-ol-0-0-10527){ref-type="table-fn"}^        15   3.053±2.036     0.909 (0.687--1.203)   0.503
  CEA           388      2.426±2.807     134              10.178±67.004   1.096 (1.039--1.157)   0.183                                                      16   3.619±3.654     1.073 (0.976--1.181)   0.216
  ALP           237      53.236±16.262   218              72.168±24.482   1.052 (1.039--1.065)   9.58×10^−20[c](#tfn3-ol-0-0-10527){ref-type="table-fn"}^   21   65.990±23.815   1.032 (1.011--1.054)   0.001^[b](#tfn3-ol-0-0-10527){ref-type="table-fn"}^
  Cholesterol   388      4.645±0.823     160              4.876±1.093     1.316 (1.076--1.610)   0.017^[a](#tfn2-ol-0-0-10527){ref-type="table-fn"}^        18   5.258±0.928     2.295 (1.332--3.956)   0.002^[b](#tfn3-ol-0-0-10527){ref-type="table-fn"}^
  TG            388      1.105±0.526     158              1.679±1.074     3.226 (2.325--4.477)   1.14×10^−9[c](#tfn3-ol-0-0-10527){ref-type="table-fn"}^    18   1.708±0.940     2.774 (1.594--4.827)   0.015^[a](#tfn2-ol-0-0-10527){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001. SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; CA, sugar chain antigen; AFP, α fetoprotein; CEA, carcino-embryonic antigen; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.

###### 

Comparison of seven serum indices by age variation in normal controls.

                Age                                                               
  ------------- ----- --------------- ---- --------------- ---------------------- ---------------------------------------------------------
  CA-125        163   17.189±8.718    27   11.888±5.823    0.868 (0.794--0.950)   0.003^[b](#tfn6-ol-0-0-10527){ref-type="table-fn"}^
  CA-199        150   10.528±7.794    21   14.414±9.310    1.051 (1.001--1.104)   0.038^[a](#tfn5-ol-0-0-10527){ref-type="table-fn"}^
  AFP           257   3.240±2.151     38   3.602±2.350     1.069 (0.932--1.226)   0.339
  CEA           257   2.355±3.005     38   2.469±1.974     1.012 (0.910--1.126)   0.821
  ALP           150   51.600±15.236   27   67.630±21.335   1.047 (1.023--1.070)   7.57×10^−4[c](#tfn7-ol-0-0-10527){ref-type="table-fn"}^
  Cholesterol   257   4.480±0.807     37   5.203±0.663     3.143 (1.945--5.078)   3.71×10^−7[c](#tfn7-ol-0-0-10527){ref-type="table-fn"}^
  TG            257   1.015±0.466     37   1.353±0.410     3.244 (1.740--6.045)   3.75×10^−5[c](#tfn7-ol-0-0-10527){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001. CA, sugar chain antigen; AFP, α fetoprotein; CEA, carcino-embryonic antigen; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.

###### 

Comparison of the seven serum indices by age variation in normal controls, patients with SCC and patients with AC.

  A, Normal                                                                                                                       
  ----------------- ---------------- ------------------ --------------------------------- --------------- ----------------------- ----------------------------------------------------------
  CA-125            163              17.189±8.718       56                                16.850±8.691    0.995 (0.960--1.032)    0.802
  CA-199            150              10.528±7.794       49                                9.249±6.476     0.975 (0.930--1.023)    0.301
  AFP               257              3.240±2.151        92                                4.129±3.180     1.136 (1.039--1.243)    0.014^[a](#tfn8-ol-0-0-10527){ref-type="table-fn"}^
  CEA               257              2.355±3.005        93                                2.605±2.529     1.028 (0.952--1.109)    0.474
  ALP               150              51.600±15.236      60                                50.850±12.791   0.996 (0.976--1.018)    0.737
  Cholesterol       257              4.480±0.807        94                                4.876±0.776     1.852 (1.360--2.523)    4.84×10^−5[c](#tfn10-ol-0-0-10527){ref-type="table-fn"}^
  TG                257              1.015±0.466        94                                1.252±0.650     2.214 (1.400--3.502)    0.002^[b](#tfn9-ol-0-0-10527){ref-type="table-fn"}^
                                                                                                                                  
  **B, SCC**                                                                                                                      
                                                                                                                                  
                    **Age**                                                                                                       
                                                                                                                                  
                    **\<40 years**   **40--50 years**   **\<40 years vs. 40--50 years**                                           
                                                                                                                                  
  **Serum index**   **n**            **Mean ± SD**      **n**                             **Mean ± SD**   **OR (95% CI)**         **P-value**
                                                                                                                                  
  CA-125            14               19.107±8.060       54                                21.213±21.154   1.007 (0.971--1.044)    0.717
  CA-199            11               14.271±11.415      46                                19.029±28.154   1.009 (0.976--1.043)    0.587
  AFP               12               4.603±3.513        53                                2.722±1.187     0.660 (0.473--0.920)    0.093
  CEA               12               4.047±8.508        54                                3.991±6.923     0.999 (0.915--1.090)    0.981
  ALP               28               56.843±13.926      97                                64.723±18.471   1.028 (1.001--1.056)    0.039^[a](#tfn8-ol-0-0-10527){ref-type="table-fn"}^
  Cholesterol       18               4.508±0.691        67                                4.563±1.015     1.065 (0.610--1.858)    0.828
  TG                18               1.273±0.678        67                                1.395±0.713     1.313 (0.579--2.974)    0.518
                                                                                                                                  
  **C, AC**                                                                                                                       
                                                                                                                                  
                    **Age**                                                                                                       
                                                                                                                                  
                    **\<40 years**   **40--50 years**   **\<40 years vs. 40--50 years**                                           
                                                                                                                                  
  **Serum index**   **n**            **Mean ± SD**      **n**                             **Mean ± SD**   **OR (95% CI)**         **P-value**
                                                                                                                                  
  CA-125            4                17.625±10.356      4                                 37.000±35.849   1.040 (0.962--1.124)    0.365
  CA-199            4                14.740±8.105       3                                 12.550±6.856    0.950 (0.753--1.198)    0.722
  AFP               4                2.115±1.051        3                                 4.023±1.932     4.236 (0.351--51.105)   0.149
  CEA               4                5.020±6.482        4                                 2.880±2.929     0.890 (0.624--1.269)    0.569
  ALP               5                58.180±7.811       6                                 66.167±41.732   1.011 (0.965--1.058)    0.686
  Cholesterol       4                4.878±0.970        5                                 4.850±0.768     0.953 (0.168--5.395)    0.963
  TG                4                1.360±0.920        5                                 1.604±0.544     1.808 (0.218--15.012)   0.633

P\<0.05

P\<0.01

P\<0.001. SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; CA, sugar chain antigen; AFP, α fetoprotein; CEA, carcino-embryonic antigen; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.

###### 

Comparison of serum indexes by The International Federation of Gynecology and Obstetrics staging in normal controls and patients with AC.

                Normal   Stage I AC      Normal vs. Stage I AC   Stage II AC     Normal vs. Stage II AC   Stage III/IV                                           Normal vs. AC (Stage III/IV)                                                                                      
  ------------- -------- --------------- ----------------------- --------------- ------------------------ ------------------------------------------------------ ------------------------------ --------------- ---------------------- ------- --- ------- ----------------------- -------
  ALP           237      53.236±16.262   15                      62.227±15.191   1.028 (1.001--1.055)     0.038^[a](#tfn11-ol-0-0-10527){ref-type="table-fn"}^   6                              75.400±38.388   1.042 (1.011--1.073)   0.217   0   0       N/A                     N/A
  Cholesterol   388      4.645±0.823     12                      5.223±0.960     2.178 (1.142--4.153)     0.017^[a](#tfn11-ol-0-0-10527){ref-type="table-fn"}^   5                              5.172±0.969     2.056 (0.767--5.512)   0.156   1   6.100   5.071 (0.826--31.145)   0.078
  TG            388      1.105±0.526     12                      1.794±1.130     2.798 (1.539--5.084)     0.059                                                  5                              1.512±0.412     2.131 (0.858--5.290)   0.086   1   1.650   2.305 (0.437--12.167)   0.302

P\<0.05. AC, cervical adenocarcinoma; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.

###### 

Comparison of the serum indices by The International Federation of Gynecology and Obstetrics staging in normal controls and patients with SCC.

                Normal   SCC (Stage I)   Normal vs. Stage I SCC   SCC (Stage II)   Normal vs. Stage II SCC   SCC (Stage III/IV)                                         Normal vs. Stage III/IV SCC                                                                                                                                                   
  ------------- -------- --------------- ------------------------ ---------------- ------------------------- ---------------------------------------------------------- ----------------------------- --------------- ---------------------- ----------------------------------------------------------- ---- ---------------- ---------------------- ----------------------------------------------------------
  CA-125        246      16.530±8.573    55                       15.629±8.479     0.987 (0.951--1.024)      0.481                                                      59                            28.295±27.882   1.045 (1.024--1.068)   0.002^[b](#tfn13-ol-0-0-10527){ref-type="table-fn"}^        23   68.283±170.741   1.039 (1.011--1.068)   0.16
  CA-199        220      10.614±7.762    45                       18.647±27.147    1.035 (1.011--1.06)       0.055                                                      49                            14.215±20.104   1.023 (0.998--1.049)   0.223                                                       20   17.853±26.946    1.037 (1.004--1.071)   0.246
  AFP           387      3.487±2.475     52                       3.348±2.222      0.975 (0.860--1.107)      0.7                                                        57                            2.984±1.429     0.886 (0.755--1.040)   0.135                                                       20   2.195±0.820      0.457 (0.263--0.796)   0.02^[a](#tfn12-ol-0-0-10527){ref-type="table-fn"}^
  ALP           237      53.236±16.262   109                      69.613±24.087    1.045 (1.030--1.060)      1.33×10^−9[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^   84                            74.073±24.918   1.054 (1.038--1.070)   1.07×10^−10[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^   25   76.908±24.400    1.055 (1.034--1.077)   6.49×10^−5[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^
  Cholesterol   388      4.645±0.823     69                       4.947±0.988      1.498 (1.115--2.011)      0.007^[b](#tfn13-ol-0-0-10527){ref-type="table-fn"}^       71                            4.932±1.196     1.414 (1.073--1.863)   0.056                                                       20   4.433±1.002      0.731 (0.422--1.269)   0.267
  TG            388      1.105±0.526     69                       1.745±1.325      2.857 (1.917--4.257)      1.77×10^−4[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^   69                            1.654±0.888     3.054 (2.084--4.476)   3.72×10^−6[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^    20   1.535±0.623      2.433 (1.370--4.324)   4.61×10^−4[c](#tfn14-ol-0-0-10527){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001. SCC, squamous cell carcinoma; CA, sugar chain antigen; AFP, α fetoprotein; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.

###### 

Adjusted assessment of the serum indices by aspartate aminotransferase and alanine transferase in normal controls and patients with cervical cancer.

                Normal   SCC             Normal vs. SCC   AC              Normal vs. AC                                                                                                                   
  ------------- -------- --------------- ---------------- --------------- ---------------------- ------------------------------------------------------------ ---- --------------- ---------------------- ------------------------------------------------------
  CA-125        238      16.692±8.634    118              29.815±77.010   1.028 (1.011--1.046)   0.067                                                        13   19.592±26.488   1.020 (0.981--1.060)   0.701
  CA-199        214      10.613±7.723    99               15.477±21.506   1.026 (1.006--1.046)   0.031^[a](#tfn15-ol-0-0-10527){ref-type="table-fn"}^         10   10.642±7.048    1.000 (0.921--1.087)   0.991
  AFP           374      3.510±2.502     113              2.904±1.645     0.862 (0.761--0.976)   0.003^[b](#tfn16-ol-0-0-10527){ref-type="table-fn"}^         13   3.075±2.198     0.912 (0.679--1.224)   0.537
  CEA           375      2.431±2.812     117              11.202±71.674   1.099 (1.040--1.161)   0.188                                                        13   3.703±3.827     1.074 (0.972--1.186)   0.114
  ALP           229      52.856±16.006   200              71.745±23.407   1.055 (1.041--1.068)   1.503×10^−19[c](#tfn17-ol-0-0-10527){ref-type="table-fn"}^   17   62.459±13.607   1.030 (1.005--1.057)   0.017^[a](#tfn15-ol-0-0-10527){ref-type="table-fn"}^
  Cholesterol   375      4.639±0.819     148              4.839±1.024     1.289 (1.040--1.598)   0.035^[a](#tfn15-ol-0-0-10527){ref-type="table-fn"}^         14   5.306±0.958     2.436 (1.333--4.452)   0.003^[b](#tfn16-ol-0-0-10527){ref-type="table-fn"}^
  TG            375      1.100±0.523     146              1.655±1.081     3.160 (2.250--4.440)   1.535×10^−8[c](#tfn17-ol-0-0-10527){ref-type="table-fn"}^    14   1.540±0.709     2.384 (1.256--4.525)   0.038^[a](#tfn15-ol-0-0-10527){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001. SCC, squamous cell carcinoma; AC, cervical adenocarcinoma; CA, sugar chain antigen; AFP, α fetoprotein; CEA, carcino-embryonic antigen; ALP, alkaline phosphatase; TG, triglyceride; SD, standard deviation; OR, odds ratio; CI, confidence interval.
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